Effect of Ganoderma lucidum extract on adipocyte differentiation and adiponectin gene expression in the murine pre-adipocyte cell line, 3T3-L1

Phytotherapy Research

Volumn 25, Issue 2, 2011, Pages 202-207

  Shimojo, Yosuke ^a   Kosaka, Kunio ^a   Shirasawa, Takuji ^b  

^a Osaka City University Medical School   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

adipocyte; adiponectin; Ganoderma lucidum; metabolic syndrome; PPAR

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADIPONECTIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; GANODERMA LUCIDUM EXTRACT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR GAL4;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL STRAIN 3T3 L1; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; METABOLIC SYNDROME X; NONHUMAN; PROADIPOCYTE; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING;

3T3-L1 CELLS; ADIPOCYTES; ADIPONECTIN; ANILIDES; ANIMALS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; MATERIA MEDICA; MICE; PPAR ALPHA; PPAR GAMMA; PROMOTER REGIONS, GENETIC; REISHI;

GANODERMA LUCIDUM; MURINAE;

EID: 79551664967     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3242     Document Type: Article

References (28)

1. Alessi MC, Poggi M, Juhan-Vague I,. 2007. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol 18: 240-245.
2. Andreelli F, Foretz M, Knauf C, et al. 2006. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 147: 2432-2441.
3. Bluher M,. 2009. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 117: 241-250.
4. Boh B, Berovic M, Zhang J, Zhi-Bin L,. 2007. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 13: 265-301.
5. Chang LC, Huang KC, Wu YW, et al. 2009. The clinical implications of blood adiponectin in cardiometabolic disorders. J Formos Med Assoc 108: 353-366.
6. Guerre-Millo M,. 2008. Adiponectin: an update. Diabetes Metab 34: 12-18.
7. Gustafson B, Jack MM, Cushman SW, Smith U,. 2003. Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha-evidence for differential regulation of the aP2 and adiponectin genes. Biochem Biophys Res Commun 308: 933-939.
8. Huang PL,. 2009. A comprehensive definition for metabolic syndrome. Dis Model Mech 2: 231-237.
9. Iseki K,. 2008. Metabolic syndrome and chronic kidney disease: a Japanese perspective on a worldwide problem. J Nephrol 21: 305-312.
10. Iwaki M, Matsuda M, Maeda N, et al. 2003. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52: 1655-1663.
11. Kadowaki T, Yamauchi T,. 2005. Adiponectin and adiponectin receptors. Endocr Rev 26: 439-451.
12. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K,. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116: 1784-1792.
13. Kim JH, Bachmann RA, Chen J,. 2009. Interleukin-6 and insulin resistance. Vitam Horm 80: 613-633.
14. Komoda Y, Shimizu M, Sonoda Y, Sato Y,. 1989. Ganoderic acid and its derivatives as cholesterol synthesis inhibitors. Chem Pharm Bull 37: 531-533.
15. Kubota N, Terauchi Y, Kubota T, et al. 2006. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 281: 8748-8755.
16. Li Khva R, Vasil'ev AV, Orekhov AN, Tertov VV, Tutel'ian VA,. 1989. [Anti-atherosclerotic properties of higher mushrooms (a clinico-experimental investigation)]. Vopr Pitan Jan-Feb (1): 16-19.
17. Li S, Shin HJ, Ding EL, van Dam RM,. 2009. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302: 179-188.
18. Long YC, Zierath JR,. 2006. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116: 1776-1783.
19. Maeda N, Takahashi M, Funahashi T, et al. 2001. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094-2099.
20. Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M,. 2008. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem 114: 183-194.
21. Park BH, Qiang L, Farmer SR,. 2004. Phosphorylation of C/EBPbeta at a consensus extracellular signal-regulated kinase/glycogen synthase kinase 3 site is required for the induction of adiponectin gene expression during the differentiation of mouse fibroblasts into adipocytes. Mol Cell Biol 24: 8671-8680.
22. Qiao L, Maclean PS, Schaack J, et al. 2005. C/EBPalpha regulates human adiponectin gene transcription through an intronic enhancer. Diabetes 54: 1744-1754.
23. Sanodiya BS, Thakur GS, Baghel RK, Prasad GB, Bisen PS,. 2009. Ganoderma lucidum: a potent pharmacological macrofungus. Curr Pharm Biotechnol 10: 717-742.
24. Shetty S, Kusminski CM, Scherer PE,. 2009. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 30: 234-239.
25. Tao J, Feng KY,. 1990. Experimental and clinical studies on inhibitory effect of Ganoderma lucidum on platelet aggregation. J Tongji Med Univ 10: 240-243.
26. Yamauchi T, Hara K, Kubota N, et al. 2003. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord 3: 243-254.
27. Yamauchi T, Kamon J, Minokoshi Y, et al. 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-1295.
28. Yuen JW, Gohel MD,. 2005. Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutr Cancer 53: 11-17.